openPR Logo
Press release

Recurrent Malignant Glioma - Pipeline Review, Industry Analysis, Growth, Trends, and Forecast Report 2017

07-07-2017 01:52 PM CET | Health & Medicine

Press release from: Market Analysis Report

Market Analysis Report

Market Analysis Report

Market Research Hub (MRH) has recently announced the addition of a fresh report, titled “Recurrent Malignant Glioma - Pipeline Review, H1 2017” to its report offerings. The report provides an overview of the Recurrent Malignant Glioma (Oncology) pipeline landscape.

Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1216999

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Recurrent Malignant Glioma - Pipeline Review, H1 2017, provides an overview of the Recurrent Malignant Glioma (Oncology) pipeline landscape.

Recurrent malignant glioma is defined as recurrence of tumor after treatment. Symptoms include chest pain due to a tumor located in the chest area of the spinal cord, erectile dysfunction, lack of ability to feel changes in temperature, loss of muscle control, loss of bowel or bladder control, numbness or tingling, pain in the arm, neck, back, or leg caused by tumors in the neck area of the spinal cord and weakness in the limbs or upper body. Treatment includes chemotherapy and radiation therapy

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Recurrent Malignant Glioma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Recurrent Malignant Glioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Recurrent Malignant Glioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Recurrent Malignant Glioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Phase I stages are 3 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 3, 2 and 1 molecules, respectively.

Recurrent Malignant Glioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Recurrent Malignant Glioma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Recurrent Malignant Glioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Recurrent Malignant Glioma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Recurrent Malignant Glioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Recurrent Malignant Glioma (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Recurrent Malignant Glioma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Recurrent Malignant Glioma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Read Full Report with TOC: http://www.marketresearchhub.com/report/recurrent-malignant-glioma-pipeline-review-h1-2017-report.html

Table of Contents:
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Recurrent Malignant Glioma - Overview
Recurrent Malignant Glioma - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Recurrent Malignant Glioma - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Recurrent Malignant Glioma - Companies Involved in Therapeutics Development
AbbVie Inc
GtreeBNT Co Ltd
Recurrent Malignant Glioma - Drug Profiles
2X-111 - Drug Profile
Product Description
Mechanism Of Action

About Market Research Hub:
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Details:
90 State Street,
Albany, NY 12207,
United States
Toll Free: 866-997-4948 (US-Canada)
Tel: +1-518-621-2074
Email: press@marketresearchhub.com
Website: http://www.marketresearchhub.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Recurrent Malignant Glioma - Pipeline Review, Industry Analysis, Growth, Trends, and Forecast Report 2017 here

News-ID: 613141 • Views: 107

More Releases from Market Analysis Report

Global Uncompensated Crystal Oscillator Industry Analysis, Growth, Trends, and F …
Market Research Hub (MRH) has recently announced the addition of a fresh report, titled “Global Uncompensated Crystal Oscillator Market Research Report 2017” to its report offerings. The report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Uncompensated Crystal Oscillator in these regions, from 2012 to 2022 (forecast). Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1220154 The global Uncompensated Crystal Oscillator market is valued at USD
Global Nanostructured Carbon Composite Market - Industry Analysis, Trends, and F …
Market Research Hub (MRH) has recently announced the addition of a fresh report, titled “Global Nanostructured Carbon Composite Market Research Report 2017” to its report offerings. The report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Nanostructured Carbon Composite in these regions, from 2012 to 2022 (forecast). Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1217158 The global Nanostructured Carbon Composite market is valued at USD
Global Instant Soups Market - Industry Analysis, Size, Share, Trends, and Foreca …
Market Research Hub (MRH) has recently announced the addition of a fresh report, titled “Global Instant Soups Market Research Report 2017” to its report offerings. The report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Instant Soups in these regions, from 2012 to 2022 (forecast). Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1041695 The global Instant Soups market is valued at USD XX million in
Prostate Cancer - Pipeline Review, Industry Analysis, Size, Trends, and Forecast …
Market Research Hub (MRH) has recently announced the addition of a fresh report, titled “Prostate Cancer - Pipeline Review, H1 2017” to its report offerings. The report covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1217005 The Pharmaceutical and Healthcare disease pipeline guide Prostate Cancer - Pipeline Review, H1 2017, provides an overview of the Prostate

All 5 Releases


More Releases for Recurrent

RWR Pilot Training Provides PA46 Recurrent Pilot Program With Master Instructor …
Accepted and approved by FAA Industry Training Standards, the FAA and the US insurance industry, RWR’s recurrent PA46 pilot training offers the best value to PA46 pilots. Baltimore, MD – December 19, 2018: With an aim to improve pilot safety and comfort, RWR Pilot Training offers a one-day and a two-day PA46 recurrent training program at competitive prices to pilots across the world. Under the guidance and support of Dick Rochfort,
Panic Disorders Market recurrent and unexpected demand foreseen in 2025
Global Panic Disorders Market: Snapshot Panic disorders, also known as anxiety disorder deals with recurrent and unexpected panic attacks. These attacks are sudden and can affect the health of a person on a serious note if untreated. As a result, several drugs and therapeutics have been introduced in order to treat patients suffering from panic disorders across the globe. The rising demand for effective drugs and the rising awareness regarding its
Global Therapies for Resistant and Recurrent Metastatic Cancer Market Status and …
Qyresearchreports include new market research report "Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size, Status and Forecast 2022" to its huge collection of research reports. The global market for Therapies for Resistant and Recurrent Metastatic Cancer is analyzed in a detailed market research report added to the extensive research report database of QYResearchReports.com. The report analyses the current state of the Therapies for Resistant and Recurrent Metastatic Cancer market
Recurrent Glioblastoma Multiforme Gbm Treatment Market to Record an Exponential …
Glioblastoma multiforme (GBM) is the most common and aggressive malignant brain tumor in humans that involves glial cells. GBM is present in two variants namely, giant cell glioblastoma and gliosarcoma. Gliomas are tumors arising from glial cells and may occur in the spinal cord or the brain, the latter being more common. Gliomas are the most common type of brain tumor and can be either supratentorial or infratentorial. Seizure,
Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market, 2016 - 2022
Glioblastoma multiforme (GBM) is the most common and aggressive malignant brain tumor in humans that involves glial cells. GBM is present in two variants namely, giant cell glioblastoma and gliosarcoma. Gliomas are tumors arising from glial cells and may occur in the spinal cord or the brain, the latter being more common. Gliomas are the most common type of brain tumor and can be either supratentorial or infratentorial. Seizure,
Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market, 2016 - 2022
Glioblastoma multiforme (GBM) is the most common and aggressive malignant brain tumor in humans that involves glial cells. GBM is present in two variants namely, giant cell glioblastoma and gliosarcoma. Gliomas are tumors arising from glial cells and may occur in the spinal cord or the brain, the latter being more common. Gliomas are the most common type of brain tumor and can be either supratentorial or infratentorial. Seizure,